New York, NY / ACCESSWIRE / October 13, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Manhattan Scientifics, Inc. (OTCQB: MHTX).
"Central to the MHTX investment thesis is the ongoing development of the company’s revolutionary cancer screening MRX technology. MHTX has had significant news flow throughout 2014 on its commercialization efforts, and on October 8th, the company announced that John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. The poster concluded that Senior Scientific’s MRX technology "is unparalleled in terms of sensitivity" compared to imaging-based ovarian cancer detection methods, such as Transvaginal Ultrasound (TVU)," commented Ajay Tandon, CEO of SeeThruEquity. "We maintain and reiterate our price target of $0.25 per share."
The link to the results can be found here - MD Anderson Results.
Highlights of the note are as follows:
MD Anderson presents MRX technology
Central to the MHTX investment thesis is the ongoing development of the company’s revolutionary cancer screening MRX technology. MHTX has had significant news flow throughout 2014 on its commercialization efforts, and on October 8th, the company announced that John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. The poster concluded that Senior Scientific’s MRX technology "is unparalleled in terms of sensitivity" compared to imaging-based ovarian cancer detection methods, such as Transvaginal Ultrasound (TVU). The poster also noted that, "Because the technology relies on nanoparticles (NPs) binding to specific cancer cells and is detecting molecular markers, only cancer will presumably be detected with this technology while unbound particles in the vascular space will not be detected. Another advantage of nanomagnetic relaxometry compared to some imaging-based technologies is that it does not expose patients to potentially harmful ionizing radiation and, because this technology is considered to be safe for human use, we expect that human studies could begin within the next five years. Thus, nanomagnetic relaxometry holds promise for detecting ovarian cancer much earlier, which is crucial to increasing survivorship."
The MRX technology holds numerous advantages over current standard screening methods, including significantly increased sensitivity. Based on unpublished data, MD Anderson has shown the technology to be up to 200 times more sensitive than current imaging technologies. Based on our discussions with MHTX, we believe it will prove to be far more sensitive than that. The MRX technology is more like a blood test, using the NPs to target specific cancer cells. Traditional imaging technologies rely on "visualization of the shape and other physical properties of the tumor," according to the presentation. It is generally believed that very early detection of cancers may well lead to their early elimination prior to metastasis and growth, and the MRX technology should be able to locate and measure cancers with a sensitivity that would provide a diagnosis years before other known methods.
MRX commercialization efforts remain company focus
MHTX hopes to accelerate its FDA submissions and has retained PharmaDirections, a professional consulting firm that has ushered some 22 pharmaceutical and medical device companies through the "labyrinth" of the FDA.
The note is available at: MHTX Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s.
Please review important disclosures on our website at www.seethruequity.com.
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nanomedicine space. The company is pursuing its "licensing" business model. The company's ultra-fine grain metals titanium application has been licensed to a Fortune/1000 NYSE company positioning the company's Metallicum unit as cash flow positive.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
SOURCE: SeeThruEquity